Violation Tracker Parent Company Summary
Parent Company Name:
AbbVie
Ownership Structure:
publicly traded (ticker symbol ABBV)
Headquartered in:
Illinois
Major Industry:
pharmaceuticals
Specific Industry:
pharmaceuticals
Penalty total since 2000:
$3,473,489,112
Number of records:
48
| Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
|---|---|---|
| healthcare-related offenses | $2,908,816,703 | 11 |
| government-contracting-related offenses | $435,190,629 | 23 |
| competition-related offenses | $84,850,000 | 6 |
| consumer-protection-related offenses | $24,826,957 | 2 |
| financial offenses | $15,000,000 | 1 |
| Top 5 Primary Offense Types | Penalty Total | Number of Records |
|---|---|---|
| off-label or unapproved promotion of medical products | $2,908,700,000 | 10 |
| False Claims Act and related | $435,190,629 | 23 |
| price-fixing or anti-competitive practices | $43,350,000 | 3 |
| kickbacks and bribery | $41,500,000 | 3 |
| consumer protection violation | $24,826,957 | 2 |
Notes:
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links:
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
Company |
Primary Offense Type | Year | Agency | Penalty Amount |
|---|---|---|---|---|
| Abbott Laboratories | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $339,148,643 |
| Abbott Laboratories | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
| Abbott Laboratories | False Claims Act and related | 2009 | AL-AG | $14,833,333 |
| Abbott Laboratories | False Claims Act and related | 2013 | LA-AG | $6,200,000 |
| Abbott Laboratories | False Claims Act and related | 2008 | PA-AG | $6,950,000 |
| Abbott Laboratories and Fournier Industrie et Sante and Laboratoires Fournier S.A. | price-fixing or anti-competitive practices | 2010 | MULTI-AG | $22,500,000 |
| Abbott Laboratories Inc. | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Abbott Laboratories Inc. | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
| Abbott Laboratories Inc. | False Claims Act and related | 2009 | OH-AG | $1,340,000 |
| Abbott Laboratories Inc. | False Claims Act and related | 2008 | TX-AG | $28,000,000 |
| Abbott Laboratories, Inc. | False Claims Act and related | 2009 | IA-AG | $357,000 |
| Abbott Laboratories, Inc. | False Claims Act and related | 2013 | ID-AG | $1,000,000 |
| ABBOTT LABS - N. CHICAGO PLANT | environmental violation | 2006 | EPA | $475,672 |
| ABBOTT LABS - N. CHICAGO PLANT | environmental violation | 2011 | EPA | $135,756 |
| ABBOTT LABS-N CHICAGO PLANT | environmental violation | 2004 | EPA | $162,595 |
| AbbVie Inc. | kickbacks and bribery | 2018 | MULTI-AG | (*) $1,800,000 |
| AbbVie Inc. | False Claims Act and related | 2019 | IL-AG | $13,747,929 |
| AbbVie Inc. | consumer protection violation | 2020 | CA-INS | $24,000,000 |
| Actavis | False Claims Act and related | 2012 | LA-AG | $4,000,000 |
| Actavis Kadian, LLC | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
| ACTAVIS,INC. | environmental violation | 2015 | EPA | $30,800 |
| Allergan | off-label or unapproved promotion of medical products | 2022 | WV-AG | $78,000,000 |
| Allergan Finance LLC | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
| Allergan Inc. | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Allergan Inc. | investor protection violation | 2017 | SEC | $15,000,000 |
| Allergan Inc. | False Claims Act and related | 2018 | USAO | $3,500,000 |
| Allergan Inc. | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $14,750,000 |
| Allergan Ltd. | off-label or unapproved promotion of medical products | 2022 | RI-AG | $7,500,000 |
| Allergan Ltd. et al. | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
| Forest Laboratories | False Claims Act and related | 2009 | AL-AG | $14,833,333 |
| Forest Laboratories | False Claims Act and related | 2013 | LA-AG | $3,000,000 |
| Forest Laboratories | False Claims Act and related | 2013 | TX-AG | $3,000,000 |
| Forest Laboratories and Forest Pharmaceuticals | False Claims Act and related | 2016 | DOJ_CIVIL | $38,000,000 |
| Forest Laboratories Inc. | False Claims Act and related | 2019 | IL-AG | $7,089,034 |
| Forest Laboratories LLC | False Claims Act and related | 2016 | MULTI-AG | (*) $2,500,000 |
| Forest Laboratories, Inc. | employment discrimination | 2018 | private lawsuit-federal | $4,000,000 |
| Forest Laboratories, Inc. | False Claims Act and related | 2012 | ID-AG | $790,000 |
| Forest Pharmaceuticals Inc. | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| Forest Pharmaceuticals Inc. | False Claims Act and related | 2010 | USAO | $149,000,000 |
| Forest Pharmaceuticals Inc. | False Claims Act and related | 2010 | MULTI-AG | (*) $60,000,000 |
| Forest Pharmaceuticals Inc. | False Claims Act and related | 2012 | KY-AG | $1,750,000 |
| Knoll Pharmaceuticals | consumer protection violation | 2001 | AR-AG | $826,957 |
| Kos Pharmaceuticals | kickbacks and bribery | 2010 | FDA | $41,500,000 |
| Kos Pharmaceuticals | kickbacks and bribery | 2010 | MULTI-AG | (*) $4,454,432 |
| Warner Chilcott Holdings | price-fixing or anti-competitive practices | 2007 | MULTI-AG | $5,500,000 |
| Warner Chilcott PLC | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Warner Chilcott PLC | False Claims Act and related | 2015 | MULTI-AG | (*) $10,600,000 |
| Watson/Schein Pharmaceuticals Inc. | False Claims Act and related | 2011 | TX-AG | $11,300,000 |
